Literature DB >> 28177074

The Consequences of Treating Asymptomatic Malaria Parasitemia.

Nicholas J White1.   

Abstract

Entities:  

Keywords:  P. falciparum; malaria risk; malaria therapy; treatment regimens

Mesh:

Year:  2017        PMID: 28177074      PMCID: PMC5849094          DOI: 10.1093/cid/ciw852

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
( Immunity to malaria is hard won, and yet it is imperfect. In areas of high malaria transmission, most symptomatic malaria and nearly all severe malaria and malaria deaths are in young children. This is the pattern in much of the malaria-endemic areas of West Africa, which bear the brunt of global malaria morbidity and mortality. Across the Sahel transmission of malaria is intense during the 3–4 rainy season months, then it declines to almost zero in the longer dry season. In these areas symptomatic malaria is a rainy season disease of young children. Older children become progressively less likely to be ill when infected, and adults are largely asymptomatic, yet at any time a high proportion of the community harbors malaria parasites in their blood. How important is this asymptomatic parasite carriage in maintaining immunity and thus protection against malaria illness? In this issue of Clinical Infectious Diseases, Portugal et al. address this question in a detailed longditudinal cohort study conducted in Kalifabougou, a rural village in Mali of ~5000 inhabitants with intense rainy season transmission of malaria typical of much of the Sahel region [1]. In the dry season between December and July there was almost no malaria transmission and therefore no symptomatic malaria, yet 46% of villagers aged between 6 months and 25 years had P. falciparum parasitemia detected by a polymerase chain reaction (PCR) assay, which has a limit of detection of 500–1000 parasites/mL. Genotyping in this and other studies strongly suggests that these parasites were carried in the blood throughout the dry season. Several studies have shown that detectable parasitemia before the rainy season is associated with a lower risk of symptomatic malaria during it. If these chronic infections were important in maintaining protective immunity, then treating them might predispose to more severe infections in the next rainy season. This prospective study shows clearly that this is not the case. Treatment of these asymptomatic infections with artemether-lumefantrine was not associated with an increased risk of symptomatic malaria in the following two rainy seasons. Furthermore, the decline in antibody profiles against 862 different P. falciparum parasite proteins was similar in infected and uninfected individuals. There seems no downside, at least in the near term, to reducing asymptomatic malaria. So should we be treating everyone with antimalarial drugs during the dry season in these areas of seasonal high transmission? In addition to the deployment of insecticide treated bed nets and prompt diagnosis and treatment of symptomatic malaria, the primary strategy currently recommended to reduce morbidity and mortality from falciparum malaria across the Sahel is seasonal malaria chemoprevention (SMC). This involves giving monthly treatment doses of amodiaquine and sulfadoxine-pyrimethamine to all children under 5 years of age during the 3–4 month rainy season. SMC has been shown to be 75% protective against uncomplicated and severe malaria. It is cost-effective and it is safe and can be administered by community-health workers. An estimated 25 million west African children aged between 3 months and 5 years could benefit from SMC every year. The role of dry season mass treatments is unclear. The weight of current opinion favors use of this approach only for elimination (ie, in areas where malaria transmission is generally low) or for epidemic containment. In low-transmission settings asymptomatic carriage rates can still be high, and mass treatment can be used to eliminate malaria rapidly. However, one of the arguments against this approach is that mass treatments would “interfere with immunity and predispose to severe malaria;” a similar concern to that in high transmission settings. But in this very different context the objective is to eliminate malaria, so it is inevitable that any protective immunity will eventually be lost if the effort is successful—emphasizing the critical importance of sustaining elimination effectively once it has been achieved.
  1 in total

1.  Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection.

Authors:  Silvia Portugal; Tuan M Tran; Aissata Ongoiba; Aboudramane Bathily; Shanping Li; Safiatou Doumbo; Jeff Skinner; Didier Doumtabe; Younoussou Kone; Jules Sangala; Aarti Jain; D Huw Davies; Christopher Hung; Li Liang; Stacy Ricklefs; Manijeh Vafa Homann; Philip L Felgner; Stephen F Porcella; Anna Färnert; Ogobara K Doumbo; Kassoum Kayentao; Brian M Greenwood; Boubacar Traore; Peter D Crompton
Journal:  Clin Infect Dis       Date:  2017-03-01       Impact factor: 9.079

  1 in total
  3 in total

1.  Submicroscopic malaria cases play role in local transmission in Trenggalek district, East Java Province, Indonesia.

Authors:  Heny Arwati; Subagyo Yotopranoto; Etik Ainun Rohmah; Din Syafruddin
Journal:  Malar J       Date:  2018-01-05       Impact factor: 2.979

2.  High cases of submicroscopic Plasmodium falciparum infections in a suburban population of Lagos, Nigeria.

Authors:  Florence A Umunnakwe; Emmanuel T Idowu; Olusola Ajibaye; Blessed Etoketim; Samuel Akindele; Aminat O Shokunbi; Olubunmi A Otubanjo; Gordon A Awandare; Alfred Amambua-Ngwa; Kolapo M Oyebola
Journal:  Malar J       Date:  2019-12-19       Impact factor: 2.979

3.  Prevalence of Asymptomatic Malaria Parasitemia in Odisha, India: A Challenge to Malaria Elimination.

Authors:  Preeti Kumari; Swati Sinha; Renuka Gahtori; Chander Prakash Yadav; Madan Mohan Pradhan; Manju Rahi; Veena Pande; Anupkumar R Anvikar
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.